KPTI

Karyopharm to Report Second Quarter 2022 Financial Results on August 4, 2022

Retrieved on: 
Thursday, July 28, 2022
Endometrial cancer, United Kingdom, Industry, Twitter, KPTI, Ruxolitinib, Therapy, Multiple myeloma, NASDAQ, Conference, SINE, Company, XPO1, Science, LinkedIn, Microdeletion syndrome, Pharmaceutical industry

NEWTON, Mass., July 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, August 4, 2022, to discuss the financial results and other company updates.

Key Points: 
  • ET --
    NEWTON, Mass., July 28, 2022 /PRNewswire/ --Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2022 financial results on Thursday, August 4, 2022.
  • ET on Thursday, August 4, 2022, to discuss the financial results and other company updates.
  • Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis.
  • For more information about our people, science and pipeline, please visit www.karyopharm.com , and follow us on Twitter at @Karyopharm and LinkedIn .

Karyopharm to Participate at the Jefferies Healthcare Conference

Retrieved on: 
Wednesday, June 1, 2022
United Kingdom, Science, Company, KPTI, Endometrial cancer, Conference, Ruxolitinib, LinkedIn, Multiple myeloma, Microdeletion syndrome, Nasdaq, XPO1, SINE, Twitter, Industry, Pharmaceutical industry

NEWTON, Mass., June 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 9:30 a.m.

Key Points: 
  • NEWTON, Mass., June 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 9:30 a.m.
  • Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies.
  • Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in multiple myeloma, endometrial cancer, myelodysplastic syndromes and myelofibrosis.
  • For more information about our people, science and pipeline, please visit www.karyopharm.com , and follow us on Twitter at @Karyopharm and LinkedIn .

Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress

Retrieved on: 
Friday, May 13, 2022
Genta (company), SD, Greater, Lymphatic system, Death, Company, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Survival, Solar cycle 1, Nasdaq, European Hematology Association, Patient, Science, Multiple myeloma, ORR, PRS, MM, FDA, SEHK, NDAS, IND, Hematology, B-cell lymphoma, Congress, HIV disease progression rates, KPTI, NDA, Therapy, Tumor suppressor gene, Cancer, Drug discovery, Diagnosis, Hong Kong Stock Exchange, XPO1, VI, Risk, Annual report, Pharmaceutical industry, Vaccine

"Antengene has made it a priority to focus on developing therapies for relapsed and refractory patients with cancer.

Key Points: 
  • "Antengene has made it a priority to focus on developing therapies for relapsed and refractory patients with cancer.
  • "We are excited to share this latest and very encouraging data on selinexor at the EHA2022.
  • These data underscore our commitment to elaborating the clinical experience for selinexor and bringing new data to the oncology community."
  • Patients were heavily pre-treated, having received a median of 9.5 prior regimen (range 5-12), with a median time from initial diagnosis of 5.2 years.

Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Tuesday, May 10, 2022
United Kingdom, SINE, Twitter, Nasdaq, Company, Microdeletion syndrome, KPTI, Industry, Endometrial cancer, Ruxolitinib, LinkedIn, Science, XPO1, Conference, Therapy, Pharmaceutical industry

NEWTON, Mass., May 10, 2022 /PRNewswire/ --Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 4:35 p.m.

Key Points: 
  • NEWTON, Mass., May 10, 2022 /PRNewswire/ --Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference on Tuesday, May 17, 2022 at 4:35 p.m.
  • Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies.
  • Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in endometrial cancer, myelodysplastic syndromes and myelofibrosis.
  • For more information about our people, science and pipeline, please visit www.karyopharm.com , and follow us on Twitter at @Karyopharm and LinkedIn .

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, May 2, 2022
Board, United Kingdom, SINE, Employment, Twitter, Nasdaq, RSU, Company, Microdeletion syndrome, Professional Football Compensation Committee, KPTI, Industry, Endometrial cancer, Ruxolitinib, LinkedIn, Science, XPO1, Financial compensation, Pharmaceutical industry

These equity awards were granted as of April 29, 2022 pursuant to the Company's 2022 Inducement Stock Incentive Plan.

Key Points: 
  • These equity awards were granted as of April 29, 2022 pursuant to the Company's 2022 Inducement Stock Incentive Plan.
  • These equity awards were granted pursuant to the Company's 2022 Inducement Stock Incentive Plan as an inducement material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
  • Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company pioneering novel cancer therapies.
  • XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc.

Aldeyra Therapeutics Announces Chief Financial Officer Transition

Retrieved on: 
Thursday, April 28, 2022
Biotechnology, Pharmaceutical, Optical, Health, Accounting, Allergic conjunctivitis, LinkedIn, Ophthalmology, Controller, Director, Retinitis pigmentosa, Patient, Twitter, Nasdaq, Business school, Therapy, Toxicity, Technology, LLP, Clark University, Interim, MKS Instruments, Company, Duane syndrome, Ernst & Young, Harvard Bioscience, Market for corporate control, Forecasting, Business, Berklee College of Music, Board, HBIO, Knowledge, Industry, KPTI, CFO, CPA, RASP, Interim management, Economics, Inflammation, Management, Medicine, Finance, Facebook

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Chief Financial Officer (CFO) and Treasurer Joshua Reed tendered his resignation to pursue other career opportunities.

Key Points: 
  • Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Chief Financial Officer (CFO) and Treasurer Joshua Reed tendered his resignation to pursue other career opportunities.
  • During his tenure, Joshua has played an integral role in executing on our strategic financial and business objectives, stated Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra.
  • Since joining Aldeyra at the end of 2019, Bruce has contributed significant expertise in the areas of financial analysis, budgeting, and forecasting, Dr. Brady stated.
  • His extensive knowledge of Aldeyra, together with his significant industry and financial experience, are well suited to help us execute our strategic priorities.

Karyopharm to Report First Quarter 2022 Financial Results on May 5, 2022

Retrieved on: 
Thursday, April 28, 2022
SINE, LinkedIn, Endometrial cancer, Twitter, Nasdaq, Ruxolitinib, XPO1, Therapy, Conference, United Kingdom, Company, Science, Microdeletion syndrome, Industry, KPTI, Pharmaceutical industry

NEWTON, Mass., April 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2022 financial results on Thursday, May 5, 2022. Karyopharm's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, May 5, 2022, to discuss the financial results and other company updates.

Key Points: 
  • ET --
    NEWTON, Mass., April 28, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2022 financial results on Thursday, May 5, 2022.
  • ET on Thursday, May 5, 2022, to discuss the financial results and other company updates.
  • Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in endometrial cancer, myelodysplastic syndromes and myelofibrosis.
  • XPOVIO and NEXPOVIO are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.

Karyopharm to Participate at the Canaccord Genuity Horizons in Oncology Conference

Retrieved on: 
Thursday, April 7, 2022
XPO1, Company, LinkedIn, United Kingdom, Ruxolitinib, Conference, KPTI, Industry, Endometrial cancer, Twitter, Nasdaq, SINE, Science, Canaccord Genuity, Microdeletion syndrome, Pharmaceutical industry

NEWTON, Mass., April 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference.

Key Points: 
  • NEWTON, Mass., April 7, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in a fireside chat at the Canaccord Genuity Horizons in Oncology Conference.
  • The conference is being conducted in a virtual format and the fireside chat will take place on Thursday, April 14, 2022 at 9:30 a.m.
  • Karyopharm has a focused pipeline targeting multiple high unmet need cancer indications, including in endometrial cancer, myelodysplastic syndromes and myelofibrosis.
  • For more information about our people, science and pipeline, please visit www.karyopharm.com , and follow us on Twitter at @Karyopharm and LinkedIn .

MedPacto Hires Global Clinical Expert Timothy R. Allen as Executive Vice President

Retrieved on: 
Thursday, March 24, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, MSD, Drug development, Therapy, GSK, Center for Drug Evaluation and Research, Degenerative disease, EVP, Regulatory affairs, Center for Biologics Evaluation and Research, Durvalumab, BMS, Pembrolizumab, Cros, CNS, PD-1, AstraZeneca, TGF, Roche, Cancer, Center, KPTI, KOSDAQ, MS, Drug, Bladder cancer, RA, FDA, PD-L1, CDER, Merck, Pharmaceutical industry, Fine chemical, Research, Sanofi

MedPacto, Inc. (KOSDAQ: 235980), a genome-based drug discovery and clinical-stage biotechnology company, is accelerating its global clinical capabilities reinforcement by recruiting global clinical experts.

Key Points: 
  • MedPacto, Inc. (KOSDAQ: 235980), a genome-based drug discovery and clinical-stage biotechnology company, is accelerating its global clinical capabilities reinforcement by recruiting global clinical experts.
  • MedPacto announced on March 24th that it has recently appointed global clinical expert and former lead clinician at KaryoPharm, Dr. Timothy R. Allen as the EVP of Clinical Development at MedPacto Therapeutics, a U.S. corporation.
  • He most recently served as Vice President of Clinical Development at KaryoPharm (KPTI), a publicly-traded global biopharmaceutical company with a focus on drug development in oncology.
  • Currently, MedPacto is conducting global clinical trials with 'Vactosertib', a TGF- inhibitor, in collaboration with global pharmaceutical companies.

Karyopharm Names New Head of Investor Relations

Retrieved on: 
Monday, March 14, 2022
Rubius, University, Risk, U.S. Securities and Exchange Commission, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Roche Diagnostics, Adoption, Ruxolitinib, Finance Secretary (India), Therapy, Union, Adult, LinkedIn, Patent, Industry, United Kingdom, Company, CFA, Patient, Biotechnology, SEC, Awareness, Private Securities Litigation Reform Act, Elhan Kastrati, El Rubius, Research, KPTI, Security (finance), B-cell lymphoma, SINE, Investor relations, Boğaziçi University, Roche, Nasdaq, Multiple myeloma, Senior, Twitter, Business development, Investment, Endometrial cancer, Master of Business Administration, Science, BB, Health care, Business administration, COVID-19, XPO1, Food, Microdeletion syndrome, Management, Pharmaceutical industry, Economics

NEWTON, Mass., March 14, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Elhan Webb as Senior Vice President of Investor Relations.  

Key Points: 
  • "Elhan has a proven track record of building best-in-class investor relations functions, and she will leverage this expertise to drive awareness and understanding ofKaryopharm's strong portfolio, pipeline and vision for the future.
  • Most recently, she served as Vice President of Investor Relations at Rubius Therapeutics.
  • Previously, she was responsible for heading investor relations at Radius Health and Genfit.
  • During her time at Roche Investor Relations, Ms. Webb led Investor Relations activities for Roche Diagnostics.